Pacific Biosciences Of California (PACB) Change in Accured Expenses (2010 - 2026)

Pacific Biosciences Of California's Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $5.1 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 118.76% year-over-year to $5.1 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 755.56% increase from a year earlier, with the FY2025 full-year figure at -$1.2 million, up 95.47% from the prior year.
• Change in Accured Expenses improved to $5.1 million in Q1 2026 per PACB's latest filing, from $1.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $22.7 million in Q2 2024 and bottomed at -$25.6 million in Q3 2024.
• The 5-year median for Change in Accured Expenses is -$1.6 million (2025), against an average of -$761823.5.
• Biggest YoY gain for Change in Accured Expenses was 747.36% in 2024; the steepest drop was 867.54% in 2024.
• Year by year, Change in Accured Expenses stood at -$2.0 million in 2022, then jumped by 666.27% to $11.0 million in 2023, then plunged by 97.08% to $323000.0 in 2024, then soared by 217.65% to $1.0 million in 2025, then surged by 400.19% to $5.1 million in 2026.
• Per Business Quant, the three latest PACB Change in Accured Expenses figures stand at $5.1 million (Q1 2026), $1.0 million (Q4 2025), and -$1.6 million (Q3 2025).